Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Ellin L. Bloch (1940-2018).

Sammons MT, DeLeon PH.

Am Psychol. 2019 Jul-Aug;74(5):628. doi: 10.1037/amp0000447.

PMID:
31305110
2.

Control of p53-dependent transcription and enhancer activity by the p53 family member p63.

Karsli Uzunbas G, Ahmed F, Sammons MA.

J Biol Chem. 2019 Jul 5;294(27):10720-10736. doi: 10.1074/jbc.RA119.007965. Epub 2019 May 21.

PMID:
31113863
3.

p63 establishes epithelial enhancers at critical craniofacial development genes.

Lin-Shiao E, Lan Y, Welzenbach J, Alexander KA, Zhang Z, Knapp M, Mangold E, Sammons M, Ludwig KU, Berger SL.

Sci Adv. 2019 May 1;5(5):eaaw0946. doi: 10.1126/sciadv.aaw0946. eCollection 2019 May.

4.

Comparison of genotoxic versus nongenotoxic stabilization of p53 provides insight into parallel stress-responsive transcriptional networks.

Catizone AN, Good CR, Alexander KA, Berger SL, Sammons MA.

Cell Cycle. 2019 Apr;18(8):809-823. doi: 10.1080/15384101.2019.1593643. Epub 2019 Apr 9.

5.

The dispersion-brightness relation for fast radio bursts from a wide-field survey.

Shannon RM, Macquart JP, Bannister KW, Ekers RD, James CW, Osłowski S, Qiu H, Sammons M, Hotan AW, Voronkov MA, Beresford RJ, Brothers M, Brown AJ, Bunton JD, Chippendale AP, Haskins C, Leach M, Marquarding M, McConnell D, Pilawa MA, Sadler EM, Troup ER, Tuthill J, Whiting MT, Allison JR, Anderson CS, Bell ME, Collier JD, Gürkan G, Heald G, Riseley CJ.

Nature. 2018 Oct;562(7727):386-390. doi: 10.1038/s41586-018-0588-y. Epub 2018 Oct 10.

PMID:
30305732
6.

Knowledge and use of HIV pre-exposure prophylaxis among men who have sex with men in Berlin - A multicentre, cross-sectional survey.

Werner RN, Gaskins M, Ahrens J, Jessen H, Kutscha F, Mosdzen R, Osswald W, Sander D, Schellberg S, Schwabe K, Wünsche T, Dressler C, Sammons M, Nast A.

PLoS One. 2018 Sep 13;13(9):e0204067. doi: 10.1371/journal.pone.0204067. eCollection 2018.

7.

The transcription factor Tfap2e/AP-2ε plays a pivotal role in maintaining the identity of basal vomeronasal sensory neurons.

Lin JM, Taroc EZM, Frias JA, Prasad A, Catizone AN, Sammons MA, Forni PE.

Dev Biol. 2018 Sep 1;441(1):67-82. doi: 10.1016/j.ydbio.2018.06.007. Epub 2018 Jun 19.

8.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ.

Nature. 2018 Jun;558(7709):307-312. doi: 10.1038/s41586-018-0178-z. Epub 2018 May 30.

9.

Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1).

Filipski KJ, Sammons MF, Bhattacharya SK, Panteleev J, Brown JA, Loria PM, Boehm M, Smith AC, Shavnya A, Conn EL, Song K, Weng Y, Facemire C, Jüppner H, Clerin V.

ACS Med Chem Lett. 2018 Apr 12;9(5):440-445. doi: 10.1021/acsmedchemlett.8b00013. eCollection 2018 May 10.

10.

Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.

Sammons MF, Kharade SV, Filipski KJ, Boehm M, Smith AC, Shavnya A, Fernando DP, Dowling MS, Carpino PA, Castle NA, Zellmer SG, Antonio BM, Gosset JR, Carlo A, Denton JS.

ACS Med Chem Lett. 2018 Jan 19;9(2):125-130. doi: 10.1021/acsmedchemlett.7b00481. eCollection 2018 Feb 8.

11.

Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.

Piotrowski DW, Futatsugi K, Casimiro-Garcia A, Wei L, Sammons MF, Herr M, Jiao W, Lavergne SY, Coffey SB, Wright SW, Song K, Loria PM, Banker ME, Petersen DN, Bauman J.

J Med Chem. 2018 Feb 8;61(3):1086-1097. doi: 10.1021/acs.jmedchem.7b01515. Epub 2018 Jan 23.

PMID:
29300474
12.

Microbiome sharing between children, livestock and household surfaces in western Kenya.

Mosites E, Sammons M, Otiang E, Eng A, Noecker C, Manor O, Hilton S, Thumbi SM, Onyango C, Garland-Lewis G, Call DR, Njenga MK, Wasserheit JN, Zambriski JA, Walson JL, Palmer GH, Montgomery J, Borenstein E, Omore R, Rabinowitz PM.

PLoS One. 2017 Feb 2;12(2):e0171017. doi: 10.1371/journal.pone.0171017. eCollection 2017.

13.

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.

Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, Barnitz RA, Bartman C, Bengsch B, Huang AC, Schenkel JM, Vahedi G, Haining WN, Berger SL, Wherry EJ.

Science. 2016 Dec 2;354(6316):1160-1165. Epub 2016 Oct 27.

14.

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Sammons M, Favours E, Wu J, Kurmashev D, Cosmopoulos K, Keilhack H, Klaus CR, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26218. Epub 2016 Aug 24.

15.

Lysine methylation represses p53 activity in teratocarcinoma cancer cells.

Zhu J, Dou Z, Sammons MA, Levine AJ, Berger SL.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9822-7. doi: 10.1073/pnas.1610387113. Epub 2016 Aug 17.

16.

Judy Estes Hall (1940-2015).

Sammons MT, Boucher A.

Am Psychol. 2016 Jul-Aug;71(5):450. doi: 10.1037/a0040228.

PMID:
27504582
17.

A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.

Monteith JA, Mellert H, Sammons MA, Kuswanto LA, Sykes SM, Resnick-Silverman L, Manfredi JJ, Berger SL, McMahon SB.

Mol Oncol. 2016 Oct;10(8):1207-20. doi: 10.1016/j.molonc.2016.05.007. Epub 2016 Jun 7.

18.

A Chromatin-Focused siRNA Screen for Regulators of p53-Dependent Transcription.

Sammons MA, Zhu J, Berger SL.

G3 (Bethesda). 2016 Aug 9;6(8):2671-8. doi: 10.1534/g3.116.031534.

19.

MLL1 is essential for the senescence-associated secretory phenotype.

Capell BC, Drake AM, Zhu J, Shah PP, Dou Z, Dorsey J, Simola DF, Donahue G, Sammons M, Rai TS, Natale C, Ridky TW, Adams PD, Berger SL.

Genes Dev. 2016 Feb 1;30(3):321-36. doi: 10.1101/gad.271882.115.

20.

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.

Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A, Huang J, Hua X, Arrowsmith CH, Berger SL.

Nature. 2015 Sep 10;525(7568):206-11. doi: 10.1038/nature15251. Epub 2015 Sep 2.

21.

Mitotic Stress Is an Integral Part of the Oncogene-Induced Senescence Program that Promotes Multinucleation and Cell Cycle Arrest.

Dikovskaya D, Cole JJ, Mason SM, Nixon C, Karim SA, McGarry L, Clark W, Hewitt RN, Sammons MA, Zhu J, Athineos D, Leach JD, Marchesi F, van Tuyn J, Tait SW, Brock C, Morton JP, Wu H, Berger SL, Blyth K, Adams PD.

Cell Rep. 2015 Sep 1;12(9):1483-96. doi: 10.1016/j.celrep.2015.07.055. Epub 2015 Aug 20.

22.

Recent progress in the development of small-molecule glucagon receptor antagonists.

Sammons MF, Lee EC.

Bioorg Med Chem Lett. 2015 Oct 1;25(19):4057-64. doi: 10.1016/j.bmcl.2015.07.092. Epub 2015 Aug 1. Review.

PMID:
26271588
23.

TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity.

Sammons MA, Zhu J, Drake AM, Berger SL.

Genome Res. 2015 Feb;25(2):179-88. doi: 10.1101/gr.181883.114. Epub 2014 Nov 12.

24.

Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.

Casimiro-Garcia A, Piotrowski DW, Ambler C, Arhancet GB, Banker ME, Banks T, Boustany-Kari CM, Cai C, Chen X, Eudy R, Hepworth D, Hulford CA, Jennings SM, Loria PM, Meyers MJ, Petersen DN, Raheja NK, Sammons M, She L, Song K, Vrieze D, Wei L.

J Med Chem. 2014 May 22;57(10):4273-88. doi: 10.1021/jm500206r. Epub 2014 Apr 30.

PMID:
24738581
25.

Identification of a novel conformationally constrained glucagon receptor antagonist.

Lee EC, Tu M, Stevens BD, Bian J, Aspnes G, Perreault C, Sammons MF, Wright SW, Litchfield J, Kalgutkar AS, Sharma R, Didiuk MT, Ebner DC, Filipski KJ, Brown J, Atkinson K, Pfefferkorn JA, Guzman-Perez A.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):839-44. doi: 10.1016/j.bmcl.2013.12.090. Epub 2013 Dec 28.

PMID:
24418771
26.

Modulation of adipose tissue thermogenesis as a method for increasing energy expenditure.

Sammons MF, Price DA.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):425-9. doi: 10.1016/j.bmcl.2013.12.016. Epub 2013 Dec 10. Review.

PMID:
24373722
27.

Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.

Futatsugi K, Piotrowski DW, Casimiro-Garcia A, Robinson S, Sammons M, Loria PM, Banker ME, Petersen DN, Schmidt NJ.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6239-42. doi: 10.1016/j.bmcl.2013.09.099. Epub 2013 Oct 8.

PMID:
24157365
28.

The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.

Guzman-Perez A, Pfefferkorn JA, Lee EC, Stevens BD, Aspnes GE, Bian J, Didiuk MT, Filipski KJ, Moore D, Perreault C, Sammons MF, Tu M, Brown J, Atkinson K, Litchfield J, Tan B, Samas B, Zavadoski WJ, Salatto CT, Treadway J.

Bioorg Med Chem Lett. 2013 May 15;23(10):3051-8. doi: 10.1016/j.bmcl.2013.03.014. Epub 2013 Mar 13.

PMID:
23562063
29.

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.

Pfefferkorn JA, Tu M, Filipski KJ, Guzman-Perez A, Bian J, Aspnes GE, Sammons MF, Song W, Li JC, Jones CS, Patel L, Rasmusson T, Zeng D, Karki K, Hamilton M, Hank R, Atkinson K, Litchfield J, Aiello R, Baker L, Barucci N, Bourassa P, Bourbonais F, D'Aquila T, Derksen DR, MacDougall M, Robertson A.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7100-5. doi: 10.1016/j.bmcl.2012.09.082. Epub 2012 Sep 29. Erratum in: Bioorg Med Chem Lett. 2013 Sep 1;23(17):5022. Bourbounais, Francis [corrected to Bourbonais, Francis].

PMID:
23089526
30.

Compulsive "helpfulness": or, how I learned to stop working so hard and love the group.

Sammons MT.

Int J Group Psychother. 2012 Jul;62(3):359-66. doi: 10.1521/ijgp.2012.62.3.359.

PMID:
22676782
31.

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.

Filipski KJ, Bian J, Ebner DC, Lee EC, Li JC, Sammons MF, Wright SW, Stevens BD, Didiuk MT, Tu M, Perreault C, Brown J, Atkinson K, Tan B, Salatto CT, Litchfield J, Pfefferkorn JA, Guzman-Perez A.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):415-20. doi: 10.1016/j.bmcl.2011.10.113. Epub 2011 Nov 6.

PMID:
22119466
32.

Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazoles.

Ratcliffe P, Abernethy L, Ansari N, Cameron K, Clarkson T, Dempster M, Dunn D, Easson AM, Edwards D, Everett K, Feilden H, Ho KK, Kultgen S, Littlewood P, Maclean J, McArthur D, McGregor D, McLuskey H, Neagu I, Nimz O, Nisbet LA, Ohlmeyer M, Palin R, Pham Q, Rong Y, Roughton A, Sammons M, Swanson R, Tracey H, Walker G.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4652-7. doi: 10.1016/j.bmcl.2011.01.051. Epub 2011 Jan 26.

PMID:
21723725
33.

A calmodulin-related light chain from fission yeast that functions with myosin-I and PI 4-kinase.

Sammons MR, James ML, Clayton JE, Sladewski TE, Sirotkin V, Lord M.

J Cell Sci. 2011 Jul 15;124(Pt 14):2466-77. doi: 10.1242/jcs.067850. Epub 2011 Jun 21.

34.

Studies of the mechanistic details of the pH-dependent association of botulinum neurotoxin with membranes.

Mushrush DJ, Koteiche HA, Sammons MA, Link AJ, McHaourab HS, Lacy DB.

J Biol Chem. 2011 Jul 29;286(30):27011-8. doi: 10.1074/jbc.M111.256982. Epub 2011 Jun 7.

35.

Saccharomyces cerevisiae Gis2 interacts with the translation machinery and is orthogonal to myotonic dystrophy type 2 protein ZNF9.

Sammons MA, Samir P, Link AJ.

Biochem Biophys Res Commun. 2011 Mar 4;406(1):13-9. doi: 10.1016/j.bbrc.2011.01.086. Epub 2011 Jan 28.

PMID:
21277287
36.

Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists.

Palin R, Abernethy L, Ansari N, Cameron K, Clarkson T, Dempster M, Dunn D, Easson AM, Edwards D, Maclean J, Everett K, Feilden H, Ho KK, Kultgen S, Littlewood P, McArthur D, McGregor D, McLuskey H, Neagu I, Neale S, Nisbet LA, Ohlmeyer M, Pham Q, Ratcliffe P, Rong Y, Roughton A, Sammons M, Swanson R, Tracey H, Walker G.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):892-8. doi: 10.1016/j.bmcl.2010.12.092. Epub 2010 Dec 23.

PMID:
21236666
37.

Differential regulation of unconventional fission yeast myosins via the actin track.

Clayton JE, Sammons MR, Stark BC, Hodges AR, Lord M.

Curr Biol. 2010 Aug 24;20(16):1423-31. doi: 10.1016/j.cub.2010.07.026. Epub 2010 Aug 12.

38.

Alpha-arylation of 3-aryloxindoles.

Mai CK, Sammons MF, Sammakia T.

Org Lett. 2010 May 21;12(10):2306-9. doi: 10.1021/ol100666v.

39.

A concise formal synthesis of diazonamide A by the stereoselective construction of the C10 quaternary center.

Mai CK, Sammons MF, Sammakia T.

Angew Chem Int Ed Engl. 2010 Mar 22;49(13):2397-400. doi: 10.1002/anie.200906318. No abstract available.

40.

ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.

Sammons MA, Antons AK, Bendjennat M, Udd B, Krahe R, Link AJ.

PLoS One. 2010 Feb 18;5(2):e9301. doi: 10.1371/journal.pone.0009301.

41.

Dynamic localization of G proteins in Dictyostelium discoideum.

Elzie CA, Colby J, Sammons MA, Janetopoulos C.

J Cell Sci. 2009 Aug 1;122(Pt 15):2597-603. doi: 10.1242/jcs.046300. Epub 2009 Jul 7.

42.

Prescriptive authority and psychology: a status report.

Fox RE, DeLeon PH, Newman R, Sammons MT, Dunivin DL, Baker DC.

Am Psychol. 2009 May-Jun;64(4):257-68. doi: 10.1037/a0015938.

PMID:
19449984
43.

Psychological services for returning veterans and their families: evolving conceptualizations of the sequelae of war-zone experiences.

Sammons MT, Batten SV.

J Clin Psychol. 2008 Aug;64(8):921-7. doi: 10.1002/jclp.20519.

PMID:
18615709
44.

Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene.

Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, Ashburner BP.

J Biol Chem. 2006 Sep 15;281(37):26802-12. Epub 2006 Jul 7.

45.
46.

Simultaneous analysis of phytohormones, phytotoxins, and volatile organic compounds in plants.

Schmelz EA, Engelberth J, Alborn HT, O'Donnell P, Sammons M, Toshima H, Tumlinson JH 3rd.

Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10552-7. Epub 2003 Jul 21.

47.

FRAMES: The Method in Action and the Assessment of Its Reliability.

Siegel PF, Sammons M, Dahl H.

Psychother Res. 2002 Mar 1;12(1):59-77. doi: 10.1080/713869617.

PMID:
22471332
48.

Orexin-A, an hypothalamic peptide with analgesic properties.

Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M, Jeffrey P, Cutler L, Riba I, Johns A, Porter RA, Upton N, Hunter AJ, Parsons AA.

Pain. 2001 May;92(1-2):81-90.

PMID:
11323129
49.

Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors.

Bingham S, Davey PT, Sammons M, Raval P, Overend P, Parsons AA.

Exp Neurol. 2001 Jan;167(1):65-73.

PMID:
11161594
50.

Carrageenan-induced thermal hyperalgesia in the mouse: role of nerve growth factor and the mitogen-activated protein kinase pathway.

Sammons MJ, Raval P, Davey PT, Rogers D, Parsons AA, Bingham S.

Brain Res. 2000 Sep 8;876(1-2):48-54.

PMID:
10973592

Supplemental Content

Loading ...
Support Center